NCT05476627 Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
| NCT ID | NCT05476627 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Chronic Kidney Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2025-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-07-01 with a primary completion date of 2025-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.
Eligibility Criteria
Inclusion Criteria: * The diagnosis of metabolic diseases were confirmed; * Be able to understand the process of the research; * Volunteer for participation and be able to sign the informed consent. Exclusion Criteria: * Age \<18 yrs or \>80yrs; * Patients with primary and secondary glomerular diseases * Patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and/or renal tumors; * Contraindications for MRI examination; * Pregnant or lactation patients; * Patients with unstable vital signs, failure of other organs or dysphoria.
Contact & Investigator
Limeng Chen
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT05476627 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Chronic Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05476627 currently recruiting?
Yes, NCT05476627 is actively recruiting participants. Contact the research team at liuyanpumch@163.com for enrollment information.
Where is the NCT05476627 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05476627 clinical trial?
NCT05476627 is sponsored by Peking Union Medical College Hospital. The principal investigator is Limeng Chen at Peking Union Medical College Hospital. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.